Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma

被引:52
|
作者
Bougnoux, P [1 ]
Germain, E
Chajès, V
Hubert, B
Lhuillery, C
Le Floch, O
Body, G
Calais, G
机构
[1] Hop Bretonneau, CORAD, Lab Biol Tumeurs & Clin Oncol Radiotherapie, F-37044 Tours, France
[2] Hop Bretonneau, Serv Informat Med & Hyg, F-37044 Tours, France
[3] INRA, LNSA, F-78350 Jouy En Josas, France
[4] Hop Bretonneay, UPRES EA2103, Gynecol Serv, F-37044 Tours, France
关键词
n-3 fatty acids; adipose tissue; docosahexaenoic acid; breast carcinoma; chemosensitivity;
D O I
10.1038/sj.bjc.6690281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Experimental studies indicated that long-chain polyunsaturated fatty acids may increase sensitivity of mammary tumours to several cytotoxic drugs. To evaluate this hypothesis in breast cancer, we have prospectively studied the association between levels of fatty acids stored in breast adipose tissue and the response of the tumour to chemotherapy in 56 patients with an initially localized breast carcinoma. Adipose breast tissue was obtained at the time of biopsy, and individual fatty acids were measured as a percentage of total fatty acids using capillary gas chromatography. Patients then received primary chemotherapy, combining mitoxantrone, vindesine, cyclophosphamide and 5-fluorouracil every 4 weeks. Tumour size was reassessed after three cycles of chemotherapy. Tumour response was evaluated according to World Health Organization criteria. Complete or partial response to chemotherapy was achieved in 26 patients (47%). Level of n-3 polyunsaturated fatty acids in adipose tissue was higher in the group of patients with complete or partial response to chemotherapy than in patients with no response or with tumour progression (P < 0.004). Among n-3 polyunsaturated, only docosahexaenoic acid (22:6n-3) was significantly associated with tumour response (P < 0.005). In a logistic regression analysis taking into account age, body mass index and tumour size, 22:6 n-3 level proved to be an independent predictor for chemosensitivity (P = 0.03). These results suggest that, in breast cancer, 22:6 n-3 may increase the response of the tumour to the cytotoxic agents used.
引用
收藏
页码:1765 / 1769
页数:5
相关论文
共 26 条
  • [21] The Predictive and Prognostic Role of Topoisomerase IIα and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy
    El Rebey, Hala S.
    Aiad, Hayam A. S.
    Abulkheir, Iman L.
    Asaad, Nancy Y.
    El-Wahed, Moshira M. A.
    Abulkasem, Fatma M.
    Mahmoud, Shereen F.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (03) : 167 - 178
  • [22] ANZ 0502 NeoGem: A Phase II Trial Evaluating the Efficacy and Safety of Epirubicin and Cyclophosphamide Followed by Docetaxel with Gemcitabine ( plus Trastuzumab If HER2 Positive) as Neoadjuvant Chemotherapy for Women with Large Operable or Locally Advanced Breast Carcinoma.
    McCarthy, N.
    Boyle, F.
    Bull, J.
    Leong, E.
    Simpson, A.
    Kannourakis, G.
    Gebski, V.
    Forbes, J. F.
    Wilcken, N.
    Lindsay, D. F.
    Badger, H. D.
    CANCER RESEARCH, 2011, 71
  • [23] Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
    Rosen, LS
    Gordon, D
    Kaminski, M
    Howell, A
    Belch, A
    Mackey, J
    Apffelstaedt, J
    Hussein, MA
    Coleman, RE
    Reitsma, DJ
    Chen, BL
    Seaman, JJ
    CANCER, 2003, 98 (08) : 1735 - 1744
  • [24] LAEVOFOLINIC ACID, 5-FLUOROURACIL, CYCLOPHOSPHAMIDE AND ESCALATING DOSES OF EPIRUBICIN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT IN LOCALLY ADVANCED AND/OR METASTATIC BREAST-CARCINOMA - A PHASE I-II STUDY OF THE SOUTHERN ITALY ONCOLOGY GROUP (GOIM)
    COLUCCI, G
    ROMITO, S
    GEBBIA, V
    PACILIO, G
    GIOTTA, F
    TESTA, A
    PEZZELLA, G
    DURINI, E
    AGOSTARA, B
    CARIELLO, S
    PALAZZO, S
    GEBBIA, N
    BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1245 - 1250
  • [25] Efficacy and safety of paclitaxel liposomes in combination with anti-HER-2 targeted drugs as first-line rescue therapy for HER-2-positive locally advanced or metastatic breast cancer: A retrospective, real-world study based on the Cancer Database of China National Cancer Center (NCC)
    Yue, J.
    Hui, Z.
    Ma, F.
    Zhang, J.
    Wang, S.
    Zhang, L.
    Zeng, X.
    Li, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1421 - S1421
  • [26] Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2-breast cancer harboring high-level FGFR1 gene amplification
    Damodaran, Senthil
    Andre, Fabrice
    Unni, Nisha
    Ferreira, Marta
    Giridhar, Karthik
    Daniel, Brooke
    Colleoni, Marco
    Costa, Luis
    Bachelot, Thomas
    O'Brien, Ciara
    Wright, Gail
    Shimura, Masashi
    Tomlinson, Gareth
    Gil, Maciej
    Turner, Nicholas
    CANCER RESEARCH, 2024, 84 (09)